1 – 48 of 48
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
-
Mark
Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer.
(
- Contribution to journal › Article
- 2013
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
- 2012
-
Mark
Photon activation therapy of RG2 glioma carrying Fischer rats using stable thallium and monochromatic synchrotron radiation.
(
- Contribution to journal › Article
-
Mark
Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
- 2010
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
Extracorporeal techniques for improving radioimmunotherapy of disseminated malignant tumors
2010)(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2009
-
Mark
Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
2009) 6th Annual Conference of the European-Neuroendocrine-Tumor-Society In Neuroendocrinology 90(1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
- 2008
-
Mark
High dose radioimmunotherapy combined with extracorporeal depletion in syngeneic rat tumor model. Evaluation of toxicity, therapeutic effect, and tumor model
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.517-517(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy
(
- Contribution to journal › Article
-
Mark
Combined flow cytometry and confocal laser scanning microscopy for evaluation of BR96 antibody cancer cell targeting and internalization.
(
- Contribution to journal › Article
-
Mark
Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
(
- Contribution to journal › Article
-
Mark
A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
(
- Contribution to journal › Article
-
Mark
Parametric images of antibody pharmacokinetics based on serial quantitative whole-body imaging and blood sampling
(
- Contribution to journal › Article
- 2006
-
Mark
Rat testis as a radiobiological in vivo model for radionuclides.
(
- Contribution to journal › Article
- 2005
-
Mark
Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
(
- Contribution to journal › Article
-
Mark
Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab.
(
- Contribution to journal › Article
- 2004
-
Mark
Blood pharmacokinetics of various mabs labeled with a new tri-chelating reagent for simultaneous conjugation with DOTA and biotin prior to radiolabeling
2004) 10th Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 19(4). p.540-541(
- Contribution to journal › Published meeting abstract
- 2003
-
Mark
Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
(
- Contribution to journal › Article
-
Mark
Change in Tumor-absorbed Dose due to Decrease in Mass during Fractionated Radioimmunotherapy in Lymphoma Patients.
(
- Contribution to journal › Article
- 2002
-
Mark
FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.
(
- Contribution to journal › Article
-
Mark
Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin.
(
- Contribution to journal › Article
-
Mark
Time dependence of the activity concentration ratio of red marrow to blood and implications for red marrow dosimetry.
(
- Contribution to journal › Article
-
Mark
131I-labelled anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates.
(
- Contribution to journal › Article
-
Mark
Single tumor cell uptake and dosimetry of technetium-99m Fab ' anti-CD22 in low-grade B-cell lymphoma
(
- Contribution to journal › Article
- 2001
-
Mark
Durable response to 90-yttrium-Epratuzumab (hLL2) in B-cell lymphoma failing chemotherapy by using dose-fractionation schedule
(
- Contribution to journal › Article
- 2000
-
Mark
Extracorporeal techniques in radioimmunotherapy
2000) p.223-243(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 1999
-
Mark
Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
(
- Contribution to journal › Article
- 1997
-
Mark
Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody
(
- Contribution to journal › Article
-
Mark
Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET
(
- Contribution to journal › Article
- 1996
-
Mark
Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method
(
- Contribution to journal › Article
-
Mark
Biodistribution and pharmacokinetics of 125I/131I pair-labelled biotinylated chimeric BR96 in colon carcinoma isografted rats
(
- Contribution to journal › Article
- 1995
-
Mark
Enhanced radioimmunotargeting of 125I-labeled L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption in rats
(
- Contribution to journal › Article
- 1994
-
Mark
Improving radioimmunotargeting of tumors: the impact of preloading unlabeled L6 monoclonal antibody on the biodistribution of 125I-L6 in rats
(
- Contribution to journal › Article
-
Mark
Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption
(
- Contribution to journal › Scientific review
-
Mark
Extracorporeal immunoadsorption of 125I-labeled monoclonal antibody L6.
(
- Contribution to journal › Article
-
Mark
A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio
(
- Contribution to journal › Article
- 1993
-
Mark
Improving radioimmonotargeting of tumors. Variation in the amount of L6 MAb administered, combined with an immunoadsorption system (ECIA)
(
- Contribution to journal › Article
-
Mark
Radioimmunotherapy dosimetry--a review
(
- Contribution to journal › Scientific review
- 1991
-
Mark
Evaluation of extracorporeal immunoadsorption for reduction of the blood background in diagnostic and therapeutic applications of radiolabelled monoclonal antibodies.
(
- Contribution to journal › Article